Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
Zze9JcF4cQ9Vqmhs
Listen
